The part which I believe will be confirmatory as opposed to ho hum, is that there will be an explanation of how the high concentration response confirms the role of patient selection biomarkers.
I still contend that was the thrust of Hampel's July commentary. He is vested in the S1 and to the extent Anavex has seemingly discovered a screen for "performance" he must be excited.
I just wonder with some of the claims of efficacy whether slowing of decline in a small patient pool is THAT confirmatory.
The Science will be what it proves to be. As for now, the Market has been disappointed by this Company before and is reserving judgement.